Skip to main content
. 2026 Apr 15;14(4):350. doi: 10.3390/vaccines14040350
AE Adverse event
AESI Adverse event of special interest
FDA Food and Drug Administration
GMFR Geometric mean fold rise
GMT Geometric mean titer
LLOQ Lower limit of quantitation
N-binding SARS-CoV-2 nucleoprotein-binding
NAAT Nucleic acid amplification test
SAE Serious adverse event
VE Vaccine effectiveness